These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

175 related articles for article (PubMed ID: 19483735)

  • 1. Medical oncology: Endocrine-therapy-related symptoms and breast cancer.
    Buzdar AU
    Nat Rev Clin Oncol; 2009 Jun; 6(6):309-10. PubMed ID: 19483735
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Local estrogen therapy and risk of breast cancer recurrence among hormone-treated patients: a nested case-control study.
    Le Ray I; Dell'Aniello S; Bonnetain F; Azoulay L; Suissa S
    Breast Cancer Res Treat; 2012 Sep; 135(2):603-9. PubMed ID: 22903687
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Pre-menopausal breast cancer and aromatase inhibitors: Treating a new generation of women.
    Freedman OC; Verma S; Clemons MJ
    Breast Cancer Res Treat; 2006 Oct; 99(3):241-7. PubMed ID: 16752075
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Breast cancer. Clinical practice guidelines in oncology.
    Carlson RW; Allred DC; Anderson BO; Burstein HJ; Carter WB; Edge SB; Erban JK; Farrar WB; Goldstein LJ; Gradishar WJ; Hayes DF; Hudis CA; Jahanzeb M; Kiel K; Ljung BM; Marcom PK; Mayer IA; McCormick B; Nabell LM; Pierce LJ; Reed EC; Smith ML; Somlo G; Theriault RL; Topham NS; Ward JH; Winer EP; Wolff AC;
    J Natl Compr Canc Netw; 2009 Feb; 7(2):122-92. PubMed ID: 19200416
    [No Abstract]   [Full Text] [Related]  

  • 5. Long-term outcome and prognostic value of Ki67 after perioperative endocrine therapy in postmenopausal women with hormone-sensitive early breast cancer (POETIC): an open-label, multicentre, parallel-group, randomised, phase 3 trial.
    Smith I; Robertson J; Kilburn L; Wilcox M; Evans A; Holcombe C; Horgan K; Kirwan C; Mallon E; Sibbering M; Skene A; Vidya R; Cheang M; Banerji J; Morden J; Sidhu K; Dodson A; Bliss JM; Dowsett M
    Lancet Oncol; 2020 Nov; 21(11):1443-1454. PubMed ID: 33152284
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Navigating the Challenges of Endocrine Treatments in Premenopausal Women with ER-Positive Early Breast Cancer.
    Colleoni M; Munzone E
    Drugs; 2015 Aug; 75(12):1311-21. PubMed ID: 26177891
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Safety profiles of aromatase inhibitors and selective estrogen-receptor modulators in the treatment of early breast cancer.
    Yamamoto Y; Iwase H
    Int J Clin Oncol; 2008 Oct; 13(5):384-94. PubMed ID: 18946748
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Body mass index and menopausal disorders during menopause affect vasomotor symptoms of postmenopausal Japanese breast cancer patients treated with anastrozole: a prospective multicenter cohort study of patient-reported outcomes.
    Tane K; Egawa C; Takao S; Yamagami K; Miyashita M; Baba M; Ichii S; Konishi M; Kikawa Y; Minohata J; Okuno T; Miyauchi K; Wakita K; Suwa H; Hashimoto T; Nishino M; Matsumoto T; Hidaka T; Konishi Y; Sakoda Y; Miya A; Kishimoto M; Nishikawa H; Kono S; Kokufu I; Sakita I; Kitatsuji K; Oh K; Akazawa K; Miyoshi Y
    Breast Cancer; 2017 Jul; 24(4):528-534. PubMed ID: 27730528
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Prevalence of joint symptoms in postmenopausal women taking aromatase inhibitors for early-stage breast cancer.
    Crew KD; Greenlee H; Capodice J; Raptis G; Brafman L; Fuentes D; Sierra A; Hershman DL
    J Clin Oncol; 2007 Sep; 25(25):3877-83. PubMed ID: 17761973
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [Adjuvant endocrine therapy in postmenopausal hormone-sensitive breast cancer: to start, to switch or to extend?].
    Nagykálnai T
    Magy Onkol; 2008 Jun; 52(2):133-43. PubMed ID: 18640889
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [Adjuvant endocrine therapy for postmenopausal women].
    Watanabe G; Ishida T; Ohuchi N
    Nihon Rinsho; 2012 Sep; 70 Suppl 7():636-40. PubMed ID: 23350476
    [No Abstract]   [Full Text] [Related]  

  • 12. Postmenopausal women with hormone receptor-positive breast cancer: balancing benefit and toxicity from aromatase inhibitors.
    Ingle JN
    Breast; 2013 Aug; 22 Suppl 2():S180-3. PubMed ID: 24074784
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Risk factors for joint symptoms in postmenopausal Japanese breast cancer patients treated with anastrozole: a prospective multicenter cohort study of patient-reported outcomes.
    Egawa C; Hirokaga K; Takao S; Yamagami K; Miyashita M; Baba M; Ichii S; Konishi M; Kikawa Y; Minohata J; Okuno T; Miyauchi K; Wakita K; Suwa H; Hashimoto T; Nishino M; Matsumoto T; Hidaka T; Konishi Y; Sakoda Y; Miya A; Mitsunobu M; Nishikawa H; Kono S; Kokufu I; Sakita I; Kitatsuji K; Oh K; Miyoshi Y
    Int J Clin Oncol; 2016 Apr; 21(2):262-269. PubMed ID: 26411314
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Toxicity of adjuvant endocrine therapy in postmenopausal breast cancer patients: a systematic review and meta-analysis.
    Amir E; Seruga B; Niraula S; Carlsson L; Ocaña A
    J Natl Cancer Inst; 2011 Sep; 103(17):1299-309. PubMed ID: 21743022
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Aromatase inhibitors in the adjuvant therapy of breast cancer].
    Bauerschlag D; Schem C; Maass N; Jonat W
    Gynakol Geburtshilfliche Rundsch; 2005 Jun; 45(3):132-6. PubMed ID: 15990437
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The importance of nonpharmacogenetic factors in endocrine therapy.
    McCowan C; Thompson AM
    Pharmacogenomics; 2012 Apr; 13(6):721-8. PubMed ID: 22515614
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Treatment-emergent endocrine symptoms and the risk of breast cancer recurrence: a retrospective analysis of the ATAC trial.
    Cuzick J; Sestak I; Cella D; Fallowfield L;
    Lancet Oncol; 2008 Dec; 9(12):1143-8. PubMed ID: 18976959
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Extended adjuvant endocrine therapy in hormone-receptor positive breast cancer.
    Strasser-Weippl K; Badovinac-Crnjevic T; Fan L; Goss PE
    Breast; 2013 Aug; 22 Suppl 2():S171-5. PubMed ID: 24074782
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Biological rationale for endocrine therapy in breast cancer.
    Miller WR
    Best Pract Res Clin Endocrinol Metab; 2004 Mar; 18(1):1-32. PubMed ID: 14687595
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Recent developments in aromatase inhibition as a potential treatment for oestrogen-dependent breast cancer.
    Banting L; Nicholls PJ; Shaw MA; Smith HJ
    Prog Med Chem; 1989; 26():253-98. PubMed ID: 2690184
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 9.